A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

This study is testing a new drug called CBX 12 in women with platinum-resistant or platinum-refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancer — cancers that have stopped responding to standard platinum-based chemotherapy. CBX 12 is an experimental targeted therapy being evaluated for safety and effectiveness. **You may be eligible if...** - You have high-grade serous cancer of the ovary, fallopian tube, or peritoneum confirmed by biopsy - Your cancer has progressed during or within 26 weeks of completing platinum-based chemotherapy (platinum-resistant), or progressed while actively receiving platinum (platinum-refractory) - You have received 1–2 additional treatment regimens for advanced disease (maintenance therapies like PARP inhibitors do not count as separate regimens) - You are 18 years or older with adequate organ function **You may NOT be eligible if...** - Your cancer is not high-grade serous type - You have received more than 2 additional lines of systemic therapy beyond platinum - You have serious organ dysfunction or other conditions preventing safe participation Talk to your doctor to see if this trial is right for you.